Download presentation
Presentation is loading. Please wait.
1
Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.79
Figure 1 Clinical trials are needed to explore the effects of switching repeatedly between a bio-originator and its biosimilar or between multiple biosimilars Figure 1 | Clinical trials are needed to explore the effects of switching repeatedly between a bio-originator and its biosimilar or between multiple biosimilars. The NOR-SWITCH study evaluated the transition from infliximab to its biosimilar CT‑P13. Kay, J. & Winthrop, K. L. (2017) Biosimilar switching — “To set a form upon desired change” Nat. Rev. Rheumatol. doi: /nrrheum
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.